BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Most of the UK is covered by Met Office weather warnings during Sunday as the cold start to the new year continues.

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

JGBs fall in the morning Tokyo session, tracking Friday’s price declines in U.S. Treasurys. Market participants are likely to ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next week in a grim mood.

To access these pages you must be a permanent member of University staff and registered on the UoB domain. Staff who are unable to access these pages or need additional access to student data should ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...